Novartis agrees $245m settlement over Exforge generics delay

Novartis has said it will pay $245 million to resolve civil litigation in the US, which accuses it of a 'pay for delay' scheme involving generics of its high blood pressure therapy Exforge.

ECJ backs UK regulator’s ‘pay-for-delay’ fine levied on GSK

California is first US state to ban pay-for-delay deals

EU authorities accuse Teva of breaking competition rules

Teva accused of "pay for delay" deal with Cephalon.

Mylan settles narcolepsy drug pay-for-delay case

Payment ends decade of litigation.